What is the recommended screening test for gestational diabetes mellitus (GDM) in a pregnant woman at 23 weeks gestation with a family history of Type 2 Diabetes Mellitus (T2DM)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended GDM Screening for This Patient

This patient should undergo a 75g oral glucose tolerance test (OGTT) at 24-28 weeks gestation (option C), which is the standard timing and method for universal GDM screening. 1, 2

Rationale for Standard Screening Timing

At 23 weeks gestation, this patient does not meet criteria for early screening despite having a family history of Type 2 Diabetes Mellitus. The key considerations are:

  • Family history alone (mother with T2DM) is not sufficient to warrant immediate early screening at this visit, as she lacks other high-risk criteria such as BMI ≥30 kg/m², prior GDM history, or previous delivery of a macrosomic infant 1, 2

  • Universal screening between 24-28 weeks is recommended for all pregnant women not previously diagnosed with diabetes, regardless of risk factors 3, 1

  • The 75g OGTT is the preferred one-step approach endorsed by the American Diabetes Association and International Diabetes Federation, with diagnostic thresholds of fasting ≥92 mg/dL, 1-hour ≥180 mg/dL, or 2-hour ≥153 mg/dL (any single value being diagnostic) 1, 4, 5

Why Other Options Are Incorrect

  • Option A (HbA1c at this visit): HbA1c is not recommended for GDM screening or diagnosis during pregnancy, though it may be useful for detecting pre-existing diabetes in early pregnancy 6

  • Option B (Random blood sugar at this visit): Random glucose testing is not a standard screening method for GDM and lacks the sensitivity and specificity of the OGTT 3

  • Option D (3-hour glucose tolerance test at 28-32 weeks): This represents the second step of the two-step approach (100g OGTT) used only after a positive 50g glucose challenge test, not as initial screening 1, 2

Clinical Advantages of the 75g OGTT

The one-step 75g OGTT approach offers several benefits:

  • Faster diagnosis with results available from a single test 4, 6
  • Better patient tolerance compared to the 100g load 6
  • Outcome-based criteria derived from the landmark HAPO study demonstrating correlation with adverse pregnancy outcomes 4, 7
  • International consensus supporting this methodology 4, 6

Important Follow-Up Considerations

  • Postpartum screening is mandatory: All women diagnosed with GDM should undergo 75g OGTT at 4-12 weeks postpartum using non-pregnant diagnostic criteria 1, 5

  • Lifelong surveillance required: Women with GDM history need screening for diabetes or prediabetes at least every 3 years 3, 1

  • Family history increases her baseline risk: While not triggering early screening, her maternal history of T2DM does place her at higher risk for developing GDM and future diabetes 1, 2

References

Guideline

Screening for Gestational Diabetes Mellitus in Pregnancy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Screening for Gestational Diabetes in Pregnant Women

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Screening for Gestational Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Gestational diabetes mellitus (Update 2023)].

Wiener klinische Wochenschrift, 2023

Research

Screening and Diagnosis of Gestational Diabetes Mellitus, Where Do We Stand.

Journal of clinical and diagnostic research : JCDR, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.